Scholar Rock Inc. has crossed the line separating a clinical-stage biotechnology company from a commercial drugmaker after the United States Food and Drug Administration approved ISEMBYLD, or apitegromab-mstn, for adults and children aged two years and older with spinal muscular atrophy who are already receiving a survival motor neuron 2-targeted treatment. The approval is particularly notable because ISEMBYLD targets muscle rather than replacing or augmenting survival motor neuron protein production, positioning it as a complementary treatment instead of a direct substitute for medicines such as Biogen’s Spinraza and Roche’s Evrysdi.
The Phase 3 SAPPHIRE study showed a 2.2-point improvement on the Hammersmith Functional Motor Scale-Expanded for the recommended 10 mg/kg dose compared with placebo after one year in the main efficacy population. Scholar Rock also reported that 34.2% of treated patients achieved an improvement of at least three points compared with 13.5% of placebo patients. The company has begun the United States commercial launch, with product shipments expected within days of the approval.
Why is ISEMBYLD different from the therapies already used in spinal muscular atrophy?
Modern SMA treatment has been transformed by medicines that address the underlying survival motor neuron deficiency. Spinraza, Evrysdi and Novartis’ Zolgensma have changed the natural history of a disease once associated with severe progressive disability and early mortality. Yet restoring or increasing survival motor neuron protein does not necessarily reverse all established muscle impairment, particularly in patients who already have substantial neuromuscular damage.
ISEMBYLD attacks that remaining problem from another direction. Apitegromab is a monoclonal antibody designed to bind pro- and latent forms of myostatin and inhibit myostatin activation. Because myostatin normally limits skeletal muscle growth, suppressing the pathway is intended to improve muscle function even while the patient continues treatment directed at the underlying SMA biology.
That mechanism explains why the label requires patients to be receiving an SMN2-targeted therapy. Commercially, this could be advantageous because Scholar Rock does not need to persuade physicians to abandon medicines that are already integrated into SMA care. Instead, it needs to demonstrate that adding ISEMBYLD produces enough incremental functional benefit to justify another chronic treatment.
Is a 2.2-point HFMSE benefit enough to change treatment decisions?
The answer depends partly on how neurologists and families interpret small numerical changes in a disease where maintaining or improving function can have practical consequences for independence. In SAPPHIRE, the main efficacy population consisted of patients aged two to 12 years, and the 2.2-point difference was reported as statistically significant with a nominal p-value of 0.0121. The greater proportion of patients achieving at least a three-point HFMSE improvement adds another way of viewing the result rather than relying only on the mean difference.
The safety profile will also influence real-world use. Scholar Rock said more than 500 people have received apitegromab across clinical studies, with some treated for more than seven years. In SAPPHIRE, however, fractures were reported in 9% of patients receiving the recommended 10 mg/kg dose compared with 2% on placebo, and the prescribing information identifies fractures as a safety concern requiring clinical consideration.
For clinicians, the adoption decision will therefore be a benefit-risk judgement layered onto an existing treatment plan. The fact that 98% of SAPPHIRE participants elected to continue into the ONYX long-term extension offers evidence that trial participants and investigators saw value in continued treatment, but commercial use will involve a much broader population and payer environment.
Can Scholar Rock turn an add-on therapy into a large commercial franchise?
The potential population is meaningful for a rare disease. Scholar Rock estimates that roughly 35,000 people worldwide with SMA have received an SMN-targeted therapy, creating a defined pool of patients for whom a muscle-directed adjunct could theoretically be relevant. The approved United States population includes adults and children aged two years and older already receiving an SMN2-targeted medicine.
Analyst expectations reflect the perceived opportunity. Reuters reported estimates that ISEMBYLD could reach approximately $2.1 billion in peak global sales by 2035. Scholar Rock shares rose more than 23% following the FDA decision, indicating that investors viewed approval as a major de-risking event rather than merely confirmation of an expected outcome.
Yet approval and commercial penetration are different problems. ISEMBYLD is administered by intravenous infusion, adding logistical demands for patients already managing chronic SMA care. Scholar Rock said infusions may be delivered in hospitals, infusion centres or at home depending on eligibility, and its support programme is designed to help patients navigate insurance, financial assistance and site-of-care logistics.
The payer argument will be particularly important. Because ISEMBYLD is used on top of existing therapy, reimbursement decisions could effectively involve the cost of combination treatment rather than substitution. Payers may therefore focus heavily on whether functional improvements translate into meaningful daily-life benefits, lower supportive-care needs or sustained long-term gains.
Does Scholar Rock have enough financial capacity to support the launch?
Scholar Rock entered commercialisation with a much stronger balance sheet than many first-time biotechnology launch companies. It reported $492.1 million in cash, cash equivalents and marketable securities at June 30, 2026, although the company was still loss-making and had funded part of its balance-sheet expansion through debt and its at-the-market equity programme. Scholar Rock said its existing resources under its then-current operating model were expected to fund operations and capital requirements into the second half of 2027.
That runway matters because launching a specialty therapy creates a different cost structure from running clinical trials alone. Scholar Rock has been building medical affairs, market access, sales and distribution infrastructure, and its general and administrative expenses increased as launch preparations expanded. The company also continues to fund development of apitegromab in other patient populations and indications.
Commercial success could therefore change Scholar Rock’s financing profile quickly if sales ramp strongly, while slower-than-expected uptake could keep cash consumption elevated. Investors should watch prescription starts, payer coverage, gross-to-net dynamics and whether the company needs additional financing before ISEMBYLD becomes a substantial source of internally generated cash.
Could the FDA approval validate myostatin inhibition beyond SMA?
This may ultimately be the larger strategic question. Scholar Rock is studying apitegromab in facioscapulohumeral muscular dystrophy through the Phase 2 FORGE study and continues work on younger SMA populations through the OPAL programme. It is also developing a subcutaneous formulation, which could eventually reduce the logistical burden associated with repeated intravenous administration.
The approval also arrives after years of disappointment across the broader myostatin field. Earlier attempts by multiple companies to translate myostatin inhibition into compelling clinical benefits struggled, making ISEMBYLD an important validation of the concept in a carefully selected disease setting. Success in SMA does not establish that the same approach will work across muscular disorders or metabolic conditions, but it provides human clinical and regulatory evidence that selective myostatin targeting can produce an approvable functional benefit.
For Scholar Rock, the immediate challenge is more practical. The company must convert regulatory success into physician adoption, reliable reimbursement and repeat use in an SMA population already receiving expensive advanced therapies. If it can do that, ISEMBYLD may become more than Scholar Rock’s first commercial product; it could establish muscle-directed combination treatment as a second therapeutic layer in modern SMA care.
